Tom Vanden Berghe obtained his Master's and PhD in Science (Biotechnology) in 1999 and 2005, respectively. Following his doctoral studies, he pursued postdoctoral research at the VIB-UGent Center for Inflammation Research. In 2018, he was appointed as an Assistant Professor at the University of Antwerp and Guest Professor at Ghent University. He was promoted to Associate Professor in 2023 and, through a fast-track procedure, achieved the rank of Professor in 2024.
Professor Vanden Berghe is Head of the Cell Death Signaling (CDS) research group at the University of Antwerp and leads its Ferroptosis Signaling team. Under his leadership, CDS brings together several complementary research teams, each headed by a principal investigator. These include the Epigenetic Signaling team led by Professor Wim Vanden Berghe, the Pyroptosis and Inflammasome Signaling team led by Professor Andy Wullaert, and the Structural Mass Spectrometry team led by Professor Frederik Lermyte. Together, the CDS teams investigate cell death and disease-related processes from molecular, immunological, epigenetic, proteomic and structural perspectives.
Professor Tom Vanden Berghe’s team focuses on the mechanisms, diagnosis and therapeutic modulation of ferroptosis in critical illness, brain injury, and kidney and vascular diseases. It also explores ferroptosis as a strategy for eliminating therapy-resistant cancers. His team has established a comprehensive ferroptosis platform encompassing novel candidate inhibitors and regulatory genes, ferroptosis diagnostics, and ferroptosis-based nanomedicines for cancer treatment.
Professor @ UAntwerp
Guest Professor @ UGent
Research coordinator
10% ZAP
Vascular calcification
Postdoctoral fellow
10% ZAP
Kidney disease
Ferroptosis
Epigenetics
Ferroptosis
Chronic interstitial nephritis
Ferroptosis
Chronic kidney disease
Ferroptosis
Ischemia/reperfusion injury
Ferroptosis
Mechanism lipid peroxidation
Endothelial cells
Vascular calcification
Nephrectomy
Regeneration
Precision medicine 2.0 diagnostics
Nanopore episequencing cfDNA
Critical illness
Precision medicin @ICU
Cell death intervention
Ferroptosis
Acute kidney injury
Ferroptosis
Multiple sclerosis
Experimental surgery
Bone histomorphometry
Biochemical analysis
Experimental surgery
Animal follow-up
Bone histomorphometry
Ferroptosis
Anti-cancer therapeutics
Biomedical Laboratory
Spectrometric Analyses
Ferroptosis
Nonalcoholic fatty liver disease
Ferroptosis
Anti-cancer therapeutics
Ferroptosis
Multiple sclerosis
Mechanisms of vascular calcification
Administration
Biochemical analysis
Nephrectomy induced repair
Toxin induced nephropathy
Arterial stiffness in vascular calcification
Metformin
Chronic kidney disease
Ferroptosis
Anti-cancer therapeutics
Ferroptosis
Immunogenicity
Ferroptosis
Multi organ failure
Experimental surgery
Mouse manager
Standard lab analysis
Postdoctoral fellow
Bone histomorphometry
| Title | Cited by |
|
2026
Clinical implications of ferroptosis in critical illness: a narrative review
Journal of Intensive Care, 2026
|
1
|
|
2026
Ferroptosis inhibition enhances liver and lung graft function
Cell 189 (13), 3991-4004. e26, 2026
|
9
|
|
2026
B76-13 Pharmacological Inhibition of Ferroptosis Attenuates Pulmonary Inflammation and Emphysema in Experimental Chronic Obstructive Pulmonary Disease (COPD)
American Journal of Respiratory and Critical Care Medicine 212 (Supplement_1 …, 2026
|
0
|
|
2026
Dual lipid modulation overcomes ferroptosis resistance in high-risk neuroblastoma
Cell Death & Differentiation 33 (5), 903-913, 2026
|
9
|
|
2026
Substituted phenothiazines as ferroptosis inhibitors
US Patent App. 19/113,145, 2026
|
0
|
|
2026
Dynamic profile of malondialdehyde in renal and hepatic ischemia reperfusion injury: an explorative study of internal historical samples
bioRxiv, 2026.04. 14.718142, 2026
|
0
|
|
2026
Pharmacological inhibition of ferroptosis attenuates pulmonary inflammation and emphysema in experimental COPD
ERJ Open Research 12 (suppl 18), 2026
|
0
|
|
2026
Biological rust in abdominal organ transplantation
|
0
|
|
2026
A fin-loop-like structure in GPX4 underlies neuroprotection from ferroptosis
Cell 189 (1), 287-306. e35, 2026
|
52
|
|
2025
Potential of biomarker-based enrichment strategies to identify critically ill patients for emerging cell death interventions
Cell Death & Differentiation 32 (12), 2284-2293, 2025
|
11
|
|
2025
Nanopore sequencing enables tissue-of-origin and pathogen detection in plasma cell-free DNA from critically ill patients
Cell Death Discovery 11 (1), 484, 2025
|
5
|
|
2025
Ferroptosis in Pig-to-Baboon Cardiac Xenotransplantation
XENOTRANSPLANTATION 32, 2025
|
0
|
|
2025
The Efficacy of Ferroptosis Inhibition on Ischemia–reperfusion Injury of Abdominal Organs: A Systematic Review and Meta-analysis
Transplantation 109 (10), e539-e553, 2025
|
4
|
|
2025
Oestrogen defends against kidney damage caused by iron-dependent cell death
Nature 645 (8082), 862-864, 2025
|
6
|
|
2025
RIPK1 ablation in T cells results in spontaneous enteropathy and TNF-driven villus atrophy
EMBO reports 26 (10), 2654-2682, 2025
|
0
|
|
2025
Macrophage caspase-8 inhibition accelerates necrotic core expansion in atheroma plaque in mice
Frontiers in immunology 16, 1513637, 2025
|
8
|
|
2025
Oxazole-based ferroptosis inhibitors with promising properties to treat central nervous system diseases
Journal of Medicinal Chemistry 68 (4), 4908-4928, 2025
|
18
|
|
2025
Harnessing ferroptosis for precision oncology: challenges and prospects
BMC biology 23 (1), 57, 2025
|
40
|
|
2025
Intravenous iron treatment fuels chronic kidney disease‐induced arterial media calcification in rats
The Journal of Pathology 265 (2), 172-183, 2025
|
3
|
|
2024
Improving cardiac differentiation of human pluripotent stem cells by targeting ferroptosis
Regenerative Therapy 27, 21-31, 2024
|
2
|
| Number | Name | Date |
| US9862678, EP3218357 | 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death | 2014-11-14 |
| EP3749645, CN112105601, US20210094909 | 3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.g. stroke | 2018-02-07 |
| WO2015110346, US9919048 | Targeting of interleukin-1 and -18 signaling in treatment of septic shock | 2014-01-21 |
| EP4590667, 2026/0109678 | Phenothiazine-based new ferroptosis inhibitors | 2022-09-21 |
| EP24187618 | Novel ferroptosis inhibitors - 2024 016 Ferropcam | 2024-07-10 |
| EP24187620 | Novel ferroptosis inhibitors - 2024 017 Alferopcom | 2024-07-10 |
| EP24187621.8 | Novel ferroptosis inhibitors - 2024 018 Oxaferropcom | 2024-07-10 |
